315 related articles for article (PubMed ID: 25138261)
1. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.
Chen JF; Yang KH; Zhang ZL; Chang HC; Chen Y; Sowa H; Gürbüz S
Osteoporos Int; 2015 Jan; 26(1):11-28. PubMed ID: 25138261
[TBL] [Abstract][Full Text] [Related]
2. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
[TBL] [Abstract][Full Text] [Related]
3. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.
Kung AW; Pasion EG; Sofiyan M; Lau EM; Tay BK; Lam KS; Wilawan K; Ongphiphadhanakul B; Thiebaud D
Curr Med Res Opin; 2006 May; 22(5):929-37. PubMed ID: 16709314
[TBL] [Abstract][Full Text] [Related]
4. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
9. Analysis of daily teriparatide treatment for osteoporosis in men.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
[TBL] [Abstract][Full Text] [Related]
10. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
11. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
Fujita T; Fukunaga M; Itabashi A; Tsutani K; Nakamura T
Calcif Tissue Int; 2014 Feb; 94(2):170-5. PubMed ID: 23963633
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
[TBL] [Abstract][Full Text] [Related]
13. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
14. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
15. [Daily subcutaneous injection of teriparatide : the progress and current issues].
Yano S; Sugimoto T
Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Lim SJ; Oh JK; Huang TW; Zeng YH; Wu MT; Yang HL; Cheung JP; Kim JW; Han JH; Huo L; Lin TJ; Zhou G; Wu WS
Clin Interv Aging; 2020; 15():111-121. PubMed ID: 32099341
[TBL] [Abstract][Full Text] [Related]
17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
18. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
Nakamura Y
Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
[TBL] [Abstract][Full Text] [Related]
19. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis.
Yamamoto T; Tsujimoto M; Hamaya E; Sowa H
J Bone Miner Metab; 2013 Mar; 31(2):199-205. PubMed ID: 23135345
[TBL] [Abstract][Full Text] [Related]
20. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
